Undetected SARS-CoV-2 transmission in a Malawian pregnancy cohort: A longitudinal serological surveillance study

Louise M. Randall, PhD[1*], Nicholas Kiernan-Walker[1*], Ernest Moya, PhD[2], Glory Mzembe, MD[2], Alistair R. D. McLean, PhD[1,3], Rebecca Harding, PhD[1], Ramin Mazhari, PhD[1], Gomezgani Mhango, MSc[2], Katherine L. Fielding, MBBS[1], Ivo Mueller, PhD[1,4], Martin N. Mwangi, PhD[2,5], Sabine Braat, MSc[1,3], Kamija Phiri, PhD[2], Sant-Rayn Pasricha, PhD[1,7,8], Emily M. Eriksson, PhD[1,4*+], Ricardo Ataíde, PhD[1*+]

[1] Infection and Global Health, The Walter and Eliza Hall Institute, VIC, Australia

[2] Training and Research Unit of Excellence (TRUE), Chichiri, Blantyre, Malawi

[3] Methods and Implementation Support for Clinical and Health Sciences Research Hub, University of Melbourne, Melbourne, Victoria, Australia

[4] Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia

[5] The Micronutrient Forum, Healthy Mothers Healthy Babies Consortium, Washington, DC, USA.

[6] Clinical Hematology at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia

[7] Diagnostic Hematology, The Royal Melbourne Hospital, Parkville, Australia

[8] School of Population and Global Health, University of Melbourne, Melbourne, Australia

* These authors contributed equally to the work.

+ **Corresponding authors**: Ricardo Ataíde, ataide.a@wehi.edu.au, tel: +61 (03) 9345 2555; Address: The Walter and Eliza Institute for Medical Research, 1G Royal Parade, Parkville, 3052

23 VIC, Australia, Emily M. Eriksson, eriksson@wehi.edu.au, tel: +61 (03) 9345 2555; Address: The
24 Walter and Eliza Institute for Medical Research, 1G Royal Parade, Parkville, 3052 VIC, Australia,
25
26
27

Abstract

Background: Despite COVID-19's global impact, surveillance remains challenging in resource-limited settings. This study investigated IgG to SARS-CoV-2 antigens in Malawian pregnant women participating in the REVAMP trial, where no COVID-19 clinical cases or positive SARS-CoV-2 tests were reported during the pandemic (April 2020 to September 2021).

Methods: We analysed serum samples collected from November 2018 to September 2021 from 852 pregnant women at enrolment (second trimester) and delivery, measuring IgG against five SARS-CoV-2 antigens using a multiplex bead assay. IgG to Tetanus toxoid served as a positive control, and IgG to four seasonal coronavirus antigens and Influenza A were used for context.

Findings: Women recruited after the start of the pandemic were younger than those recruited before the emergence of COVID-19 (median age 19 vs 21 years) and more likely primigravid (60.1% vs 51.1%). IgG levels to SARS-CoV-2 antigens showed sharp increases of 18.5% - 29.7% every 30 days during COVID waves 2 and 3. Overall seropositivity to SARS-CoV-2 antigens reached 39.3% during the pandemic; however, the 14.7% seropositivity detected pre-pandemic demonstrates the presence of cross-reactive antibody responses against other antigens in Malawi. Surprisingly, pregnancies within the pandemic showed improved outcomes, with longer gestations (mean difference: 0.6 weeks [95% CI: 0.2 - 0.9]) and higher birth weights (mean difference: 169.3g, [65.9 - 272.6]) when compared to pregnancies occurring pre-pandemic. We found no evidence that SARS-CoV-2 IgG levels were associated with pregnancy outcomes.

Interpretations: This study demonstrates that serological surveillance reveals undetected SARS-CoV-2 exposure where traditional testing was limited. The improvement in pregnancy outcomes during the pandemic suggests community-level exposure did not offset the social impacts of the pandemic in this population. These findings highlight pregnancy cohorts as valuable sentinel populations for infectious disease surveillance, emphasising the importance of serosurveillance in resource-limited settings.

57 Introduction:

58 The COVID-19 pandemic presented unique surveillance challenges in resource-limited settings,
59 where constrained testing capacity and limited healthcare access complicated efforts to track
60 SARS-CoV-2 transmission.[1] In Malawi, despite early public health measures, significant
61 challenges in disease surveillance and response coordination left the true extent of viral spread
62 uncertain. While official statistics suggested low case numbers, compared to other global regions,
63 limited molecular testing capacity and accessibility, particularly in rural areas, meant that actual
64 infection rates remained difficult to ascertain. [2,3]

65

66 This surveillance challenge was strikingly illustrated in the REVAMP trial—a randomized
67 controlled trial of iron supplementation in pregnancy conducted in southern Malawi.[4] Running
68 from November 2018 through September 2021, the trial spanned pre-pandemic and pandemic
69 periods, including three distinct COVID-19 waves that occurred in Malawi.[5] Despite regular
70 participant monitoring through at least four study visits between second-trimester enrolment and
71 delivery, no trial participant reported receiving a positive SARS-CoV-2 test or presented with
72 respiratory symptoms indicative of COVID-19. A seroprevalence survey of blood donations at the
73 Malawi Blood Transfusion Service, suggested that the seropositivity in Malawi could reach 65%.[6]
74 As such, the absence of reported cases within REVAMP, a closely monitored cohort going through
75 a pandemic, suggested that infections were going undetected.

76

77 Serological surveillance offers a powerful tool for addressing such detection challenges,
78 particularly when supported by appropriate validation measures. By determining antibody
79 responses rather than active infections, serosurveillance can reveal historical exposure patterns and

provide insights into population-level transmission dynamics that traditional surveillance methods might miss.[7] The value of this approach has been well-demonstrated in various infectious disease contexts.[8–11]

Pregnancy cohorts are particularly valuable for serosurveillance, as they provide year-round contact points for sample collection and monitoring.[12,13] For example, in malaria-endemic areas of Africa, serosurveillance of pregnant women is increasingly seen as a reliable and easy way to determine trends in malaria transmission across the population.[10,12,13] Additionally, pregnancy-specific interventions, such as vaccinations during governmental health programs, create built-in immunological controls that can validate changes seen in incidental serological findings— e.g. tetanus vaccination during pregnancy provides a reliable immunological stimulus that can verify both healthcare delivery and antibody detection methods.[14]

The REVAMP trial presented an ideal platform for investigating potential undetected transmission of SARS-CoV-2 through serosurveillance during pregnancy. Its timeline included reliable pre- and post-pandemic samples from the same population—rare in COVID-19 serological studies—while its regular monitoring schedule ensured consistent sample collection throughout the pandemic period. The trial's comprehensive data collection on several demographics, clinical outcomes, and healthcare delivery patterns offered multiple avenues for validating the serological findings. We aimed to leverage this unique opportunity to assess evidence of undetected SARS-CoV-2 exposure through validated serological approaches. In addition, we evaluated the impact of changes to SARS-CoV-2 serology on pregnancy outcomes.

Methods

Study design

All samples are from the REVAMP trial, which took place in southern Malawi, in the Zomba and Blantyre districts. The trial protocol, statistical analysis plan and primary results have been published.[4,15] Briefly, pregnant women with ultrasound-confirmed singleton second-trimester pregnancy were individually randomized to receive either an intravenous iron infusion of Ferric Carboxymaltose [Vifor Pharma] or standard of care oral iron if they met the eligibility criteria. Eligibility criteria included haemoglobin of <10.0g/dL (by HemoCue 301+ [Angelholm, Sweden]), and a negative malaria rapid diagnostic test, among others. The primary endpoint of the trial was anaemia prevalence at 36 weeks' gestation. Venous blood samples were taken throughout the pregnancy, including at enrolment (13-26 weeks' gestation), and delivery. Blood was processed within two hours of collection and plasma was aliquoted and stored locally at -80 ºC until being shipped to Melbourne, Australia. All women were eligible to receive pregnancy immunisations from the Malawi Government, following the national Expanded Programme of Immunisation strategy. These include a dose of Tetanus toxoid (Tt) at the first antenatal visit (often the time of first contact with the REVAMP trial team), a second dose 4 weeks after the first dose and a third dose 6 months after the second dose.[16]

The trial received ethics approvals from the College of Medicine, University of Malawi, Malawi (P.02/18/2357), and The Walter and Eliza Hall Institute (WEHI), Australia (18/02) and was prospectively registered (ACTRN12618001268235). An independent data and safety monitoring board oversaw the trial. Secondary analyses of the trial samples were included in the study protocol.

126

127 COVID-19 Setting

128 All dates related to the COVID-19 pandemic were obtained from publicly available Malawian
129 Government sources.[5] The first official case of COVID-19 in Malawi was reported on April 2nd
130 2020, and marked the beginning of the first wave of infections (Figure 1).[5] Following the
131 establishment of containment policies, and at the request of the Malawi Ministry of Health,
132 REVAMP amended its protocol and adopted COVID measures in May of 2020 (i.e. limiting the
133 number of contact visits between the team and the participants, as well as limiting the duration of
134 those visits).[15] In January 2021, the Malawi government implemented a national lockdown.
135 Vaccinations were introduced in Malawi on March 11th 2021, with the ChAdOx1-S COVID-19
136 vaccine being delivered.[5] Study participants were deliberately not asked whether they had
137 received COVID-19 vaccines as there was a lot of misconception, and it was thought that this
138 question could affect retention in subsequent visits. However, at each visit, participants were asked
139 to report any concomitant medication they were on or any prior visits to a health centre, and we
140 had no indication that any of the study participants received the vaccination. Malawi experienced
141 three waves of COVID-19 during the lifespan of REVAMP.[5] During the entire trial, there were no
142 participant self-reported nor trial team-confirmed COVID-19 cases within the cohort, and there
143 were no observed or reported positive SARS-CoV-2 tests.

144

145 Serological multiplex bead-array

146 A multiplex serological assay was used to detect antigen-specific IgG antibodies targeting the
147 SARS-CoV-2 Spike protein, Spike-derived antigens (S1, S2 and receptor binding domain (RBD))
148 and nucleoprotein (NP), as previously described.[17] Additionally, we assessed antibodies to

149 seasonal coronaviruses antigens (NL63, OC43, HKU1 and 229E) and Influenza virus A (H1N1).
150 Antibodies to Tt were also measured as an immunological positive control.[16] Briefly, individual
151 plasma samples were incubated with fluorescent magnetic beads coated with the relevant antigens.
152 Antigen-specific antibodies were then identified using a secondary anti-human IgG Fc antibody
153 conjugated to phycoerythrin (PE) and analyzed with the MAGPIX® system. All samples were run
154 with the analysts blinded to the participants' characteristics.
155
156 Statistical analysis
157 The sample size was determined by the available data of all randomised women with a plasma
158 sample at study enrolment or delivery. Baseline characteristics were summarised and compared
159 before and after COVID-19 emergence in Malawi using either two-sample t or Wilcoxon rank-
160 sum test for continuous data or chi-square or Fisher's exact test for categorical data. Antibody
161 levels were quantified as adjusted mean fluorescent intensity (aMFI) derived from standard curves.
162 Seropositivity for SARS-CoV-2 antibodies was determined as IgG levels exceeding the mean plus
163 two standard deviations from pre-pandemic pregnancies. Longitudinal $\log_e$-transformed IgG levels
164 were visualised using locally weighted (LOWESS) regression with restricted cubic spline curve,
165 and 10 smoothing points.[18] Linear regression models with two inflexion points (start of the
166 COVID-19 pandemic in Malawi - April 2nd 2020; beginning of the second COVID-19 wave -
167 January 1st 2021), resulted in three time segments. Models accounted for variables assumed to be
168 prognostic or predictive of the outcomes: maternal age, body mass index, primiparity, sex of the
169 newborn, HIV status, income source and treatment group. Estimates and confidence intervals (CI)
170 were back-transformed to reflect a per cent of change over 30 days.
171

172 Linear regression models were used to quantify associations between pregnancy outcomes of
173 interest (gestational age, birth weight and low birth weight) and serological data at delivery as
174 exposures with adjustment for confounding and prognostic variables - maternal age,
175 primigravidity, body mass index, HIV status, and treatment group. Spearman correlations assessed
176 the IgG relationships during the Pre-COVID or COVID periods. No adjustment for multiple testing
177 was done.
178
179 Small for gestational age was defined as a birthweight below the 10th percentile for gestational age
180 according to INTERGROWTH-21 standards;[19] Low birth weight is defined as a birth weight
181 <2500 g; Premature birth is a birth occurring at <37 weeks' gestation; Foetal loss represents a
182 composite of pregnancy loss and stillbirth. All statistical analyses were conducted in Stata v18.0
183 (StataCorp, College Station, TX) and GraphPad Prism v10 (GraphPad Software, San Diego, CA,
184 USA).
185
186 Results
187 Trial Population reflected COVID-19 impacts
188 The REVAMP trial recruited 862 participants between November 2018 and March 2021, with the
189 last delivery in the trial occurring in September 2021, thus pregnancies in REVAMP spanned pre-
190 pandemic and pandemic periods (Figure 1a). A total of 852/862 (98.8%) women had available
191 serum samples and were included in this nested study (Table 1), including 147 samples from
192 enrolment only, 30 samples from delivery only, and 675 samples for both enrolment and delivery.
193 The baseline characteristics of the women with a sample analysed at only one time point were
194 similar to women who had samples analysed at both time points (Table S1).

195

196 A total of 569 (66.8%) women were enrolled before and 283 (33.2%) women were enrolled after
197 April 2nd 2020, the date of the first case of COVID-19 registered in Malawi (Table 1) while 358
198 (42.0%) pregnancies were spent solely under the Pre-COVID period and 135 (15.8%) solely under
199 the COVID periods (Figure 1a).

200

201 We observed differences in demographic characteristics of the trial participants before and after
202 the emergence of COVID-19 in Malawi (Table 1). The impact of time of recruitment on
203 demographics revealed maternal age decreased across the period of the trial, from a median of 21
204 years (IQR [19-27]) in the pre-COVID period to 19 years (IQR [17-23]) (P=0.0010) during the
205 COVID period. Consistent with this, we observed an increase in the percentage of women in their
206 first pregnancy towards the end of the trial (51.1% (291/569) pre-COVID vs 60.1% (170/283)
207 COVID; P=0.014). Income source also changed significantly from the pre-COVID to the COVID
208 periods (P<0.001), with more women reporting practicing Subsistence farming (13.1% (74/567)
209 pre-COVID vs 25.9% (73/282) COVID) and less women reporting being Employed (21.2% pre-
210 COVID vs 11.4% COVID).

211

212 Serological outcomes validation – Tetanus toxoid

213 We measured antibodies to Tetanus toxoid (Tt) as a validation tool for our serological assays. As
214 was expected from Malawi's vaccination policy,[16] IgG toward Tt were higher at delivery versus
215 enrolment (Figure 1b), and in women with two or more pregnancies compared to women in their
216 first pregnancy – both at enrolment and, though to a lesser degree, at delivery (Figure 1c-d). The

overall levels of anti-Tt antibodies measured at delivery were unaffected in those pregnancies carried solely within the COVID period vs those solely in the pre-COVID period (Figure 1e).

Serological outcomes – SARS-CoV-2

Antibodies to all five of SARS-CoV-2 antigens increased from the beginning of 2021, coinciding with the emergence of COVID waves 2 and 3 in Malawi (Figure 2a and Supplementary figure 1). A wide range of IgG levels to SARS-CoV-2 antigens were present even before the emergence of the COVID-19 pandemic, indicating the occurrence of cross-reactive immune responses in this population. In general, there was a subtle positive trend in antibody levels over time, with values remaining relatively stable through to the end of COVID wave 1, followed by an increase through COVID waves 2 and 3. Linear modelling of this relationship revealed a significant increase in antibodies to SARS-CoV-2 antigens during COVID waves 2 and 3 (Figure 2b, Supplementary Table 2). This increase was also noticeable when comparing mean antibody levels in those pregnancies carried solely within the COVID period versus those occurring in the pre-COVID (Figure 2c). In addition, the correlations between IgG levels to all SARS-CoV-2 antigens also significantly increased from those pregnancies entirely in the pre-COVID period to those entirely in the COVID period (Figure 2e-d).

A total of 102 samples (17.3%) were seropositive for at least one of the SARS-CoV-2 antigens (ranging from 4.3% for RBD to 9.1% against SPIKE). Half of the 102 seropositive samples (49%) were seropositive for 1 of the antigens and only 5 samples (4.1%) were seropositive for all five SARS-CoV-2 antigens. The overall seroprevalence calculated for those pregnancies entirely outside of the COVID-19 period in Malawi was 14.7% (48/327), revealing a significant number

240 of cross-reactive responses to other antigens. In pregnancies occurring entirely within the COVID
241 period, the overall seroprevalence was 39.3% (48/122).
242
243 Serological outcomes – Seasonal coronaviruses and Influenza A
244 Antibodies to seasonal viruses presented a distinct pattern across the timeline of the trial (Figure
245 3a-b and Supplementary figure 1). LOWESS visualization showed little variation across the
246 entirety of the trial (Figure 3a). Linear modelling over the three-segments of the trial revealed a
247 general stability over the pre-COVID period— maximum variation was for IgG towards
248 Coronavirus HKU1 (mean % change over 30 days: -4.1% [-5.8, -2.3]) (Supplementary Table 2).
249 This was followed by a small increase in IgG levels during the second period, and an overall
250 decrease during the last period (Figure 3b, Supplementary Table 2). However, the levels of
251 antibodies to these common human coronaviruses, including types NL63, OC43, and HKU1, and
252 to Influenza A (H1N1) remained relatively unchanged when analysing those pregnancies occurring
253 outside or inside the COVID period, except for antibodies to Coronavirus 229E that declined
254 significantly at delivery between solely pre-COVID and solely COVID pregnancies (Figure 3c).
255 There was no significant change to the correlations between antigens to the common coronaviruses
256 and Influenza A between COVID periods (Figure 3c-d).
257
258 Pregnancy outcomes of the trial according to COVID period and association with SARS-CoV-2
259 antibodies
260 Throughout the trial, and after accounting for confounding variables, gestation duration increased
261 significantly between pregnancies that delivered during the COVID period compared to pre-
262 COVID (adjusted mean difference 0.5 weeks [0.2-0.8]) (Table 2). This difference was still

263 observed when looking at women with pregnancies entirely in the COVID period versus entirely
264 in the pre-COVID period (mean difference 0.6 weeks [0.2, 0.9]). Accordingly, babies had higher
265 birth weights when delivered during the COVID period compared with those delivered during the
266 pre-COVID period (mean difference 69.4 g [-2.4-141.1]), although this increased birthweight was
267 only significant when comparing those pregnancies occurring solely within the COVID period
268 versus occurring solely in pre-COVID (mean difference 169.3 g [65.9, 272.6]). Low birth weight
269 decreased during the COVID period (Odds Ratio (OR) COVID vs pre-COVID: 0.57 [0.37-0.89]),
270 and in those pregnancies solely occurring during COVID versus in pre-COVID (OR Solely
271 COVID vs pre-COVID: 0.40 (0.20-0.77)) (Table 2).
272
273 In women whose pregnancies occurred within the COVID period, we found no evidence of a
274 statistically significant association between seropositivity to SARS-CoV-2 antigens and pregnancy
275 outcomes. However, the estimates around the associations had very large 95% CI, which is
276 compatible with large effects in either direction (Supplementary Table 3).
277
278 Discussion
279 In this study we used samples from the REVAMP clinical trial to examine serological patterns and
280 pregnancy outcomes before and during the COVID-19 pandemic in a well-characterized cohort of
281 Malawian pregnant women. We found that, despite a lack of clinical symptoms and laboratory-
282 confirmed positive tests, levels of antibodies to key antigens of SARS-CoV-2 significantly
283 increased in the population, as did the overall seropositivity prevalence, from a background
284 estimate of 14.7% seropositivity before COVID to an overall seropositivity of 39.3% for
285 pregnancies within the COVID period. Over the full span of the trial, we observed an increase in

286 the mean gestation duration and birth weight of the babies, accompanied by a decrease in the
287 overall prevalence of low birth weight. However, we found no evidence that exposure to SARS-
288 CoV2—as measured by IgG to 5 different antigens — was associated with pregnancy and birth
289 outcomes.
290
291 The REVAMP trial commenced in November 2018 and had its last delivery in September 2021.
292 This resulted in continuous sampling throughout pregnancy and up to delivery for women before
293 the emergence of the COVID-19 pandemic and up to the height of the 2021 COVID-19 waves in
294 Malawi. We observed significant demographic shifts throughout the trial's duration. Women
295 enrolled during the pandemic were significantly younger than those enrolled in the pre-COVID
296 period. This change was accompanied by significant changes to the parity, education and income
297 source measures of the trial cohort—reflecting the younger population. This shift in population
298 age observed during our trial timeline may reflect the broader socio-economic changes that
299 occurred during the pandemic. Malawi reported a decrease in total health service attendance of up
300 to 10% from April 2020 to December 2021, with antenatal services specifically falling by 3%.[20] It
301 is reasonable to assume that, as lockdowns, school closures and other containment measures were
302 enforced by the Malawian government,[5] women with young children may have had responsibilities
303 that prevented them from either participating in the study or engage with the health services. These
304 findings also highlight the importance of understanding the characteristics of the underlying
305 population when the time periods of study are lengthy.
306
307 Our serological findings contribute to understanding immune responses to SARS-CoV-2 in
308 African pregnant women. A meta-analysis of the seroprevalence of anti-SARS-CoV-2 antibodies

309 across Africa (excluding Malawi) revealed seroprevalences ranging from 0.0-63.0%,[21] while
310 studies in Malawi, estimated prevalences at between 10-85% depending on the sampling strategy
311 and the population.[6,22,23] In REVAMP, we measured a peak seroprevalence of 39.3%. Although
312 seropositivity to SARS-CoV-2 does not immediately follow from increases in seroprevalence to
313 single antigens, the increase of antibody levels to all five SARS-CoV-2 antigens during the
314 COVID-19 period, coupled with stronger inter-antigenic correlations, suggests true community
315 transmission occurred in the trial population during this period. This timing agrees with SARS-
316 CoV-2 seroprevalence data obtained from blood donations surveyed from 4 distinct areas of
317 Malawi[6] and from pregnant women at first antenatal clinic, in a country-wide study which started
318 just as REVAMP was recruiting its last participants.[23] The general rise in antibody levels to all the
319 antigens evaluated suggests a rise in serology due to community transmission of the virus, rather
320 than through active vaccination campaigns, which only started in March of 2021 and experienced
321 low uptake until the end of 2021.[5] Notably, the relatively high individual spread of IgG levels
322 observed against SARS-CoV-2 antigens in samples collected before the emergence of SARS-CoV-
323 2—a degree of background reactivity not observed in other cohorts—[17] and raises questions about
324 potential immunological cross-reactivity between SARS-CoV-2 antigens and other antigens in this
325 population. The clinical significance of this observation remains to be determined.
326
327 IgG levels measured against common human coronaviruses as well as Influenza A revealed distinct
328 patterns to those observed against all SARS-CoV-2 antigens, with little variation across the trial
329 period. The stability of Tt antibody levels across all periods served as an important internal control,
330 demonstrating the specificity of the observed changes in antibodies to SARS-CoV-2 and other
331 control viruses. Tt vaccinations were provided by the Government, not as part of the trial, thus

332 demonstrating that despite disruptions to the health services during COVID, [20] ANC attendance
333 and services was still relatively strong in this area of Malawi.
334
335 Despite the serological evidence of increasing SARS-CoV-2 exposure in the population, during
336 the trial period, pregnancies occurring during COVID-19 experienced longer gestational ages and
337 babies with increased birth weights. As is the case with many respiratory infections,[24] SARS-CoV-
338 2 infections, and COVID-19 in particular, negatively affect birth outcomes.[25] However,
339 observations of better outcomes for pregnancy during the pandemic have been made in other
340 cohorts as well.[26] These results seem to suggest that either 1) exposure levels in our population
341 may not have reached a significant threshold; or 2) the negative impacts of SARS-CoV-2 infection
342 were of less magnitude than the improvements due to reductions in other infections during
343 COVID; or 3) The negative impact of infection is of lesser magnitude than the improvement driven
344 by a shift in the characteristics of the women recruited to the trial— reduced mobility and limited
345 physical demands may have conserved maternal energy, and increased presence of partners at
346 home may have provided added support during pregnancy.
347
348 These findings should be interpreted in context. While our study benefits from being embedded
349 within a clinical trial with standardised follow-up and data collection, this also means that our
350 findings may not apply to the broader Malawian population. We did not collect specific
351 information regarding COVID-19 vaccination status of our participants. Our study's temporal
352 nature makes it challenging to disentangle the effects of SARS-CoV-2 infection from the effects
353 of pandemic-related social and healthcare changes. While our models accounted for demographics
354 such as age and primiparity that shifted during our study, these significant demographic shifts

355 could have introduced unmeasured confounding factors not accounted for in our statistical
356 adjustments. Additionally, it's important to note that our trial population, receiving regular
357 antenatal care and nutritional supplementation, may have been relatively protected from pandemic-
358 related impacts when compared to the general population[20].
359
360 In conclusion, we demonstrate that in a population of pregnant women in Malawi, where
361 symptoms of COVID-19 were absent and there was no recorded evidence of SARS-CoV-2
362 infection, population-level IgG to SARS-CoV-2 antigens rose in alignment with well-defined
363 COVID-19 periods. In addition, the increase in inter-antigenic correlation between the antibody
364 levels to SARS-CoV-2 antigens during the COVID-19 period also sustains the interpretation that
365 there was true population transmission during the COVID pandemic. This represents additional
366 evidence to the body of research that proposes pregnancy as a sensitive sentinel period for the
367 population surveillance of infectious diseases. [11,12,27,28]

368 References

369 1 Batista C, Hotez P, Amor Y Ben, *et al.* The silent and dangerous inequity around access to
370 COVID-19 testing: A call to action Comment. *EClinicalMedicine* 2022; **43**: 101230.

371 2 Ulaya G, Kabaghe A, Saussier C, *et al.* Monitoring COVID-19 Occurrence in a Resource-
372 limited Setting – COVID-19 Sentinel Surveillance in Malawi. 2024; published online Dec
373 26. DOI:10.1101/2024.12.23.24319583.

374 3 Taylor A, Liwewe T, Todd J, Kankhwali C, Mwale A, Kiwuwa-Muyingo S. Insights into
375 COVID-19 data collection and management in Malawi: exploring processes, perceptions,
376 and data discrepancies. *Wellcome Open Res* 2024; **9**.
377 DOI:10.12688/wellcomeopenres.21131.1.

378 4 Pasricha S-R, Mwangi MN, Moya E, *et al.* Ferric carboxymaltose versus standard-of-care
379 oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised
380 controlled trial. *Lancet* 2023; **401**: 1595–609.

381 5 Presidential Task Force on Coronavirus. THE CORONAVIRUS PANDEMIC IN
382 MALAWI: TRAILING THE WAVES. 2022.

383 6 Mandolo J, Msefula J, Henrion MYR, *et al.* SARS-CoV-2 exposure in Malawian blood
384 donors: an analysis of seroprevalence and variant dynamics between January 2020 and July
385 2021. *BMC Med* 2021; **19**. DOI:10.1186/s12916-021-02187-y.

386 7 Arnold BF, Scobie HM, Priest JW, Lammie PJ. Integrated serologic surveillance of
387 population immunity and disease transmission. *Emerg Infect Dis* 2018; **24**: 1188–94.

388 8 Tedijanto C, Solomon AW, Martin DL, *et al.* Monitoring transmission intensity of trachoma
389 with serology. *Nat Commun* 2023; **14**. DOI:10.1038/s41467-023-38940-5.

390 9 Dorigatti I, Lavezzo E, Manuto L, *et al.* SARS-CoV-2 antibody dynamics and transmission
391 from community-wide serological testing in the Italian municipality of Vo'. *Nat Commun*
392 2021; **12**. DOI:10.1038/s41467-021-24622-7.
393 10 van Eijk AM, Hill J, Noor AM, Snow RW, ter Kuile FO. Prevalence of malaria infection in
394 pregnant women compared with children for tracking malaria transmission in sub-Saharan
395 Africa: A systematic review and meta-analysis. *Lancet Glob Health* 2015; **3**: e617–28.
396 11 Pujol A, Brokhattingen N, Matambisso G, *et al.* Detecting temporal and spatial malaria
397 patterns from first antenatal care visits. *Nat Commun* 2023; **14**. DOI:10.1038/s41467-023-
398 39662-4.
399 12 Ataíde R, Mayor A, Rogerson SJ. Malaria, primigravidae, and antibodies: Knowledge
400 gained and future perspectives. Trends Parasitol. 2014; **30**: 85–94.
401 13 Mayor A, Menendez C, Walker PGT. Targeting pregnant women for malaria surveillance.
402 *Trends Parasitol* 2019; : 1–10.
403 14 Integrated Management of Pregnancy and Childbirth (IMPAC). Maternal Immunization
404 against Tetanus. Integrated Management of Pregnancy and Childbirth (IMPAC). .
405 15 Harding R, Ataide R, Mwangi MN, *et al.* A Randomized controlled trial of the Effect of
406 intraVenous iron on Anaemia in Malawian Pregnant women (REVAMP): Statistical
407 analysis plan. *Gates Open Res* 2021; **5**: 174.
408 16 The Government of Malawi. EPI Comprehensive Multi-Year Plan. 2016.
409 17 Mazhari R, Ruybal-Pesántez S, Angrisano F, *et al.* SARS-CoV-2 Multi-Antigen Serology
410 Assay. *Methods Protoc* 2021; **4**. DOI:10.3390/mps4040072.
411 18 Chambers JM, Cleveland WS, Kleiner B, Tukey PA. Graphical Methods for Data Analysis.
412 Chapman and Hall/CRC, 2018 DOI:10.1201/9781351072304.

413 19 Villar J, Ismail LC, Victora CG, *et al.* International standards for newborn weight, length,
414 and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of
415 the INTERGROWTH-21st Project. *The Lancet* 2014; **384**: 857–68.
416 20 She B, Mangal TD, Adjabeng AY, *et al.* The changes in health service utilisation in Malawi
417 during the COVID-19 pandemic. *PLoS One* 2024; **19**. DOI:10.1371/journal.pone.0290823.
418 21 Chisale MRO, Ramazanu S, Mwale SE, *et al.* Seroprevalence of anti-SARS-CoV-2
419 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol. 2022; **32**.
420 DOI:10.1002/rmv.2271.
421 22 Meinus C, Singer R, Nandi B, *et al.* SARS-CoV-2 prevalence and immunity: a hospital-
422 based study from Malawi. *International Journal of Infectious Diseases* 2022; **116**: 157–65.
423 23 Tenthani L, Seffren V, Kabaghe AN, *et al.* SARS-CoV-2 Seroprevalence and Vaccine
424 Uptake among Pregnant Women at First Antenatal Care Visits in Malawi. *American Journal*
425 *of Tropical Medicine and Hygiene* 2024; **110**: 989–93.
426 24 Di Mascio D, Khalil A, Saccone G, *et al.* Outcome of coronavirus spectrum infections
427 (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am
428 J Obstet Gynecol MFM. 2020; **2**. DOI:10.1016/j.ajogmf.2020.100107.
429 25 Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. *Nat Rev*
430 *Immunol* 2022; **22**: 277–82.
431 26 de Knegt VE, Hedley PL, Hedermann G, *et al.* The impact of the COVID-19 lockdown on
432 birthweight among singleton term birth in Denmark. *PLoS One* 2023; **18**.
433 DOI:10.1371/journal.pone.0283909.
434 27 Gutman J. Pregnant women and children as sentinel populations. 2017.

28 Joint United Nations Programme on HIV/AIDS and World Health Organization. Guidelines for Conducting HIV Sentinel Serosurveys among Pregnant Women and Other Groups. 2003; : 1–106.

Acknowledgements: The Bill & Melinda Gates Foundation funded the REVAMP trial (INV-010612). S-RP is supported by the Australian National Health and Medical Research Council (NHMRC) Fellowships (GNT1158696 and GNT2009047). We thank the local field workers, participants, and their families for their involvement in the study.

Author contributions: S-RP and KSP conceptualised and designed the trial and secured funding. EM, GMz, GMh and MNM led data collection in the field. RA and EME planned this study. LMR, NK-W, and KLF conducted experimental data collection. NK-W, RM, EME and RA had full access to and analysed the data. RH, ARDM, SB and RA conducted the statistical analysis. LMR, ARDM, EME and RA interpreted the data. RA prepared the initial draft of the manuscript. All authors critically revised the manuscript for intellectual content, edited and approved the final version, and agreed to be accountable for all aspects of the work.

Data sharing: The datasets generated during this study are available from the corresponding author on reasonable request, subject to ethical approval and data sharing agreements with the REVAMP trial investigators.

Competing interests: The authors declare no competing interests.

459 **Table 1- Baseline characteristics according to the timing of the emergence of COVID-19 in**

460 **Malawi.**

	Before emergence of COVID-19 in Malawi[a]	**After emergence of COVID-19 in Malawi[b]**	**Total Cohort[§]**	**Test p-value[k]**
N, %	569 (66.8%)	283 (33.2%)	852 (100.0%)	
Age (years)	21.0 [18.0, 26.0]	19.0 [17.0, 24.0]	20.0 [18.0 25.0]	0.0010
BMI[c] (kg/m^2)	22.8 [21.1, 24.7]	22.5 [21.0, 24.5]	22.6 [21.1, 24.6]	0.20
Primigravid				
No	278 (48.9%)	113 (39.9%)	391 (45.9%)	0.014
Yes	291 (51.1%)	170 (60.1%)	461 (54.1%)	
Religion				
None	0 (0.0%)	2 (0.7%)	2 (0.2%)	0.064
Christian	419 (73.9%)	192 (68.1%)	611 (72.0%)	
Muslim	144 (25.4%)	84 (29.8%)	228 (26.9%)	
Other	4 (0.7%)	4 (1.4%)	8 (0.9%)	
Education				
None	2 (0.4%)	0 (0.0%)	2 (0.2%)	0.0020
Lower Primary	98 (17.9%)	74 (27.0%)	172 (21.0%)	
Upper Primary	215 (39.4%)	122 (44.5%)	337 (41.1%)	
Lower Secondary	85 (15.6%)	28 (10.2%)	113 (13.8%)	
Upper Secondary	132 (24.2%)	45 (16.4%)	177 (21.6%)	
Tertiary	14 (2.6%)	5 (1.8%)	19 (2.3%)	
Marital status				
Single	85 (15.0%)	47 (16.7%)	132 (15.5%)	0.57
Married	474 (83.6%)	228 (80.9%)	702 (82.7%)	
Widowed	3 (0.5%)	1 (0.4%)	4 (0.5%)	
Divorced/Separated	4 (0.7%)	5 (1.8%)	9 (1.1%)	
Others	1 (0.2%)	1 (0.4%)	2 (0.2%)	
Income source				
None	38 (6.7%)	15 (5.3%)	53 (6.2%)	<0.001
Subsistence farming	74 (13.1%)	73 (25.9%)	147 (17.3%)	
Large scale farming	1 (0.2%)	1 (0.4%)	2 (0.2%)	
Employed	120 (21.2%)	32 (11.3%)	152 (17.9%)	
Casual work for wages	162 (28.6%)	99 (35.1%)	261 (30.7%)	
Business	163 (28.7%)	59 (20.9%)	222 (26.1%)	
Other	9 (1.6%)	3 (1.1%)	12 (1.4%)	
HIV positive				
No	462 (81.8%)	239 (85.4%)	701 (83.0%)	0.19
Yes	103 (18.2%)	41 (14.6%)	144 (17.0%)	
Haemoglobin[d] (g/dL)	9.1 [8.1, 9.8]	8.7 [7.9, 9.3]	8.9 [8.0, 9.6]]	<0.001
Anaemia[e]				
No	34 (6.0%)	7 (2.5%)	41 (4.8%)	0.023
Yes	531 (94.0%)	276 (97.5%)	807 (95.2%)	
Ferritin (µg/L)	25.7 [9.4, 64.2]	28.4 [11.6, 86.8]	26.8 [10.0, 72.3]	0.95
CRP (mg/L)[f]	5.3 [2.8, 11.1]	5.0 [2.8, 9.8]	5.2 [2.8, 10.6]	0.85
Inflammation[g]				
No	269 (47.4%)	137 (51.1%)	406 (48.6%)	0.31
Yes	299 (52.6%)	131 (48.9%)	430 (51.4%)	
Iron deficiency[h]				
No	313 (55.1%)	161 (60.1%)	474 (56.7%)	0.18
Yes	255 (44.9%)	107 (39.9%)	362 (43.3%)	

461 Data are count (%) or median [25% centile, 75% centile]. [a]Women enrolled in the trial before April

462 2nd 2020. [b]Women enrolled in the trial on or after April 2nd 2020. [c]Body Mass Index.

463 [d]Haemoglobin levels in venous blood, measured by Symex. [e]Anaemia indicates proportion of

464 women with haemoglobin <11 g/dL. [f]C-Reactive Protein. [g]Inflammation indicates a CRP >5 mg/L.

465 [h]Iron deficient indicates a serum ferritin<15 µg/L, or serum ferritin<30 µg/L if CRP >5 mg/L. [k]P-
466 values relate to testing for differences between before and after emergence of COVID in Malawi.
467 The analysis included all women with available serological samples at either enrolment or
468 delivery.
469

470 **Table 2. Effects of COVID-19 period on Pregnancy and Birth Outcomes**

Delivery inside vs outside COVID	**Pre-Covid**	**Covid**	**OR [95% CI] or mean difference [95% CI]**	**P-value**
Small for gestational age n/N (%)	146/477 (30.6%)	92/266 (34.6%)	1.10 [0.79-1.53]	0.57
Low birth weight (<2,500g) n/N (%)	89/484 (18.4%)	32/265 (12.1%)	0.57 [0.37-0.89]	0.013
Premature birth (<37 weeks) n/N (%)	43/489 (8.8%)	17/270 (6.3%)	0.70 [0.39-1.26]	0.23
Fetal loss n/N (%)	11/522 (2.1%)	5/275 (1.8%)	0.95 [0.32-2.82]	0.93
Gestation duration (weeks) Mean (SD)[#]	39.3 (2.1)	39.8 (1.9)	0.49 [0.20-0.78]	0.0010
Birth weight (grams) Mean (SD)[$]	2889.9 (501.4)	2930 (477.8)	69.36 [-2.39-141.12]	0.06
Entire gestation period inside vs outside COVID				
Small for gestational age n/N (%)	94/335 (28.1%)	40/130 (30.8 %)	0.97 [0.62-1.53]	0.90
Low birth weight (<2,500g) n/N (%)	64/340 (18.8%)	12/127 (9.4%)	0.40 [0.20-0.77]	0.0070
Premature birth (<37 weeks) n/N (%)	35/343 (10.2%)	8/130 (6.2%)	0.59 [0.26-1.33]	0.20
Fetal loss n/N (%)	5/350 (1.4%)	1/132 (0.8%)	0.53 [0.05-5.19]	0.59
Gestation duration (weeks) Mean (SD)[†]	39.2 (2.2)	39.8 (1.6)	0.6 [0.2-0.9]	0.0030
Birth weight (grams) Mean (SD)[‡]	2883.2 (516.3)	3001.5 (487.4)	169.3 [65.9-272.6]	0.0010

471

472 **Note**: Small for gestational age defined as a birthweight below the 10th percentile for gestational
473 age according to INTERGROWTH-21 standards;[19] Low birth weight is defined as a a birth weight
474 < 2500 g; Premature birth is a birth occurring at <37 weeks gestation; Fetal loss represents a
475 composite of pregnancy loss and stillbirth. [#] N=489 Pre-COVID and 270 COVID. [$]N= 484 Pre-
476 COVID and 265 COVID [†]N=343 Pre-COVID and 130 COVID. [‡]N= 340 Pre-COVID and 127
477 COVID. OR - Odds Ratio; CI - Confidence Interval. All models controlled for treatment group,
478 maternal age, body mass index, primigravid status, and HIV status. Analysis were run on all
479 samples with non-missing data.


a
Pre COVID
COVID
Covid wave 1
Covid wave 2+3
Study participants (ordered by enrolment date)
-200
Start of REVAMP
Dec
Jan 2019
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan 2020
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan 2021
Feb
Mar
Apr
May
Jun
Jul
Aug
Timeline
Duration of pregnancy
Enrollment date
Official Covid-19 waves
b
Tetanus toxoid IgG (adj. MFI)
<0.0001
Enrolment
Delivery
c
Enrolment
Tetanus toxoid IgG (adj. MFI)
<0.0001
G1
G2+
d
Delivery
Tetanus toxoid IgG (adj. MFI)
0.0001
G1
G2+
e
Tetanus toxoid IgG (adj. MFI)
Solely Pre-Covid
Solely Covid

480

481 **Figure 1: Participant timelines and cohort characteristics across pre-pandemic and pandemic periods.** (a) Individual participant
482 timeline distribution across the study period. Horizontal lines represent each participant's pregnancy duration, with enrollment dates
483 marked as circles. Blue horizontal lines are pregnancies that occurred exclusively in the pre-COVID-19 period. Magenta lines are
484 pregnancies that occurred partially in the COVID-19 period. Dark red lines are pregnancies entirely occurring within the COVID-19
485 period. Shaded boxes represent reported COVID-19 waves (wave 1 – green; waves 2 and wave 3 – pink). (b) Anti-tetanus toxoid IgG
486 levels by visit date (enrolment and delivery) (unpaired Welch's t-test). (c) Anti-tetanus toxoid IgG levels at enrollment between first-
487 time pregnancies (G1) and second or higher pregnancies (G2+) (unpaired Welch's t-test). (d) anti-tetanus toxoid IgG levels at delivery
488 between first-time pregnancies (G1) and second or higher pregnancies (G2+) (unpaired t-test). (e) Anti-tetanus toxoid IgG levels between
489 pregnancies occurring entirely within the pre-COVID period (solely pre-COVID) or pregnancies that occurred exclusively during the
490 Malawi COVID-19 period (Solely COVID) (unpaired t-test). All serological values are shown as $\log_e$-transformed median fluorescence
491 intensity (MFI).
492


a
Pre COVID
COVID
Covid wave 1
Covid wave 2+3
IgG levels (adj. MFI)
Start of REVAMP
S2
NP
b
S1
S2
RBD
Spike
NP
-20
0
20
40
60
% change per 30 days
Pre-Covid
Covid wave 1
Covid wave 2+3
c
SARS-CoV-2 S1 (adj. MFI)
SARS-CoV-2 S2 (adj. MFI)
SARS-CoV-2 RBD (adj. MFI)
SARS-CoV-2 Spike (adj. MFI)
SARS-CoV-2 NP (adj. MFI)
<0.001
Solely Pre-Covid
Solely Covid
e
Solely Pre-Covid
Solely Covid
S1
S2
RBD
SPIKE
NP
d
Spearman Coefficient
<0.001
Solely Pre-Covid
Solely Covid

493

494

495 **Figure 2: Serological patterns of anti-SARS-CoV-2 antibodies during pregnancy.** (a) LOWESS smoothing curves illustrating the
496 relationship between time and anti-SARS-CoV-2 antibodies is shown for SARS-CoV-2 S2 and SARS-CoV-2 NP antigens. The analysis
497 was conducted using GraphPad Prism v10. This method fits a non-parametric regression and makes no assumptions about the functional
498 form of the relationship. The graph includes the original data points as scatter markers to allow assessment of the density and distribution
499 of observations across the range of values. (b) Mean percent change in IgG levels per 3 days across the three time periods assessed after
500 fitting a linear regression model. (c) Comparison of mean antibody levels to SARS-CoV-2 antigens between pregnancies occurring
501 outside (entirely pre-COVID) or inside (entirely COVID) the COVID period (unpaired T-test). (d) Correlation coefficient matrix
502 between antibodies measured against SARS-CoV-2 antigens in samples from pregnancies outside (Solely pre-COVID - top) or inside
503 (Solely COVID - bottom) the COVID period. (e) Comparison of mean correlation coefficient between antibodies against SARS-CoV-
504 2 antigens between pregnancies occurring outside (Solely pre-COVID) or inside (Solely COVID) the COVID period (unpaired T-test).
505


a
Pre COVID
COVID
Covid wave 1
Covid wave 2+3
IgG Levels (adj. MFI)
Start of REVAMP
Influenza A
Coronavirus NL63
b
Coronavirus 229e
Coronavirus HKU1
Coronavirus OC43
Coronavirus NL63
Influenza A (H1N1)
% change per 30 days
Pre-Covid
Covid wave 1
Covid wave 2+3
c
Coronavirus 229E (adj. MFI)
Coronavirus HKU1 (adj. MFI)
Coronavirus OC43 (adj. MFI)
Coronavirus NL63 (adj. MFI)
Influenza A H1N1 (adj. MFI)
0.003
0.26
0.11
0.60
0.43
Solely Pre-Covid
Solely Covid
e
S1 229e
SPIKE HKU1
IVA HA1
NP NL63
SPIKE OC43
Solely Pre-Covid
Solely Covid
d
Spearman Coefficient
0.28
Solely Pre-Covid
Solely Covid

506

507

508 **Figure 3: Serological patterns of anti-common Coronavirus and Influenza A (H1N1) antibodies during pregnancy.** (a) LOWESS
509 smoothing curves illustrating the relationship between time and antibodies against Influenza A (green) and Coronavirus NL63 (teal)
510 antigens. The analysis was conducted using GraphPad Prism v10. This method fits a non-parametric regression and makes no
511 assumptions about the functional form of the relationship. The graph includes the original data points as scatter markers to allow
512 assessment of the density and distribution of observations across the range of values. (b) Mean percent change in IgG levels per 30 days
513 across the three time periods assessed after fitting a linear regression model. (c) Comparison of mean antibody levels to SARS-CoV-2
514 antigens between pregnancies occurring outside (entirely pre-COVID) or inside (entirely COVID) the COVID period (unpaired T-test).
515 (d) Correlation coefficient matrix between antibodies measured against SARS-CoV-2 antigens in samples from pregnancies outside
516 (Solely pre-COVID - top) or inside (Solely COVID - bottom) the COVID period. (e) Comparison of mean correlation coefficient
517 between antibodies against SARS-CoV-2 antigens between pregnancies occurring outside (Solely pre-COVID) or inside (Solely
518 COVID) the COVID period (unpaired T-test)